Will Trinity Biotech stock go up?

According to Danelfin AI, Trinity Biotech has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (46.78%) is -4.04% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Trinity Biotech stock?

The Trinity Biotech target price is $0.38 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Trinity Biotech stock right now?

Trinity Biotech has today a Sell rating (AI Score 3/10), according to Danelfin AI. Its probability of beating the market in 3 months (46.78%) is -4.04% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Trinity Biotech stock is a good buy .

Is Trinity Biotech undervalued right now?

Based on analysts, the average price target downside for Trinity Biotech is 0.00% (1Y). According to Danelfin AI, Trinity Biotech has today an AI Score of 3/10 (Sell Rating).

What was the price range of Trinity Biotech stock over the past 12 months?

The Trinity Biotech stock price range over the past 12 months has been $0.34 - $1.91.

What is going on with Trinity Biotech stock in the last 3 months?

The Trinity Biotech stock performance in the last quarter has been -37.08%.

Does Trinity Biotech offer dividend payments?

No, Trinity Biotech does not currently pay dividends.

What is the current market capitalization of Trinity Biotech?

Trinity Biotech's market cap is $7.28M, as of 2026-07-03 08:00.

Trinity Biotech PLC (TRIB) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

TRIB AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Volatility+1.53%
How much the stock price tends to fluctuate
Momentum+0.64%
Direction and strength of recent price movements

Sentiment-4.54%
How analysts and the market view the stock
Valuation-0.65%
How the stock is priced relative to its fundamentals
Size & Liquidity-0.62%
Company size and trading liquidity
Profitability-0.41%
Profitability and operating efficiency metrics

TRIB probability advantage of beating the market (3M):

-4.04%

AI Score

Sell

Trinity Biotech (TRIB) has an AI Score of 3/10 (Sell) because, according to an overall analysis, it has a probability advantage of -4.04% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of TRIB (46.78%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
TRIB probability advantage of beating the market (3M)-4.04%
TRIB probability of beating the market (3M)46.78%

TRIB probability advantage of beating the market (3M): -4.04%

The AI-powered overall analysis of Trinity Biotech (TRIB) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of TRIB:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Industry (GICS)	Health Care Equipment & Supplies	N/A	-2.08%
Technical	ATR (14d Volatility)	0.07	N/A	+1.20%
Technical	Chart Pattern (120d)	figure_19	N/A	-1.18%
Technical	Chart Pattern (504d)	figure_38	N/A	-1.17%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.95%
Technical	Chart Pattern (180d)	figure_12	N/A	+0.90%
Technical	Alpha 1Y	-0.67%		+0.87%
Sentiment	Institutional Ownership	5.55%		-0.81%
Technical	Maximum Volatility	16.01%		-0.80%
Technical	Chart Pattern (252d)	figure_34	N/A	+0.73%
Technical	Upgrade to unlock			+0.72%
Sentiment	Upgrade to unlock			-0.71%
Sentiment	Upgrade to unlock			+0.66%
Sentiment	Upgrade to unlock			-0.65%
Technical	Upgrade to unlock			+0.64%

Rest of Alpha Signals: -1.42%

TRIB probability advantage of beating the market (3M)Total:-4.04%
TRIB AI Score

Significant changes Vs previous day

TRIB Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$0.38
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

TRIB Proven Sell Signal & Price Forecast

This is the price chart for TRIB from January 2, 2026 until today. The chart indicates, in red, the 73 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

TRIB Average Past Performance & Loss Rate

Three months after its 844 Sell signals since July 2026, TRIB had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

844 Past TRIB Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+15.36%
Average Alpha				-0.40%
Loss Rate (% Negative Perf.)				76.47%
% Negative Alpha				77.70%

TRIB Frequently Asked Questions

Will Trinity Biotech stock go up?
According to Danelfin AI, Trinity Biotech has today an AI Score of 3/10 (Sell rating), because its probability of beating the market in 3 months (46.78%) is -4.04% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Trinity Biotech stock?
Is it a good time to buy, sell, or hold Trinity Biotech stock right now?
Is Trinity Biotech undervalued right now?
What was the price range of Trinity Biotech stock over the past 12 months?
What is going on with Trinity Biotech stock in the last 3 months?
Does Trinity Biotech offer dividend payments?
What is the current market capitalization of Trinity Biotech?

Trinity Biotech PLC Company Profile

Trinity Biotech plc, accompanied by its subsidiaries, is a leading player in the development, manufacturing, and commercialisation of medical diagnostic solutions. The organisation holds a significant share in both the clinical laboratory and point-of-care (POC) segments of the global diagnostic market, spanning across continents like America, Africa, Asia and Europe.

The company's core suite of clinical laboratory products encompasses diagnostic tests and instrumentation designed to detect a wide range of infectious diseases. Conditions that can be diagnosed using these products range from lyme disease to sexually transmitted illnesses such as herpes and syphilis. Their testing equipment also identifies SARS-CoV-2 along with numerous viral pathogens including epstein barr, measles, mumps, toxoplasmosis among other viral threats.

Furthermore, Trinity Biotech provides solutions for the in-vitro diagnostic detection of haemoglobin A1c. These tools play an integral role in diagnosing and monitoring diabetes as well delivering pivotal insights into assessing risk factors associated with diabetes progression.

In addition to this extensive portfolio of services, they offer specialised laboratory-testing for autoimmune disorders encompassing Sjogren’s syndrome, hearing loss alongside celiac disease. They also have reliable diagnostic solutions for rheumatoid arthritis and systemic sclerosis among others.

Their product line uses an array of technology formats including immunofluorescence assay (IFA), enzyme-linked immunosorbent assay (ELISA), western blotting method and line immunoassay techniques. They also create reagent products essential for diagnosis liver ailments and kidney diseases as well as hemolytic anaemia - these include tests for substances like ACE, bile acids,lactate oxalate among others including glucose-6-phosphate dehydrogenase.

Trinity Biotech additionally serves as a raw material provider to diverse players within the life sciences industry along with research institutes.

Their delivery networks are robustly supported through direct sales force units while leveraging their relations with independent distributors and strategic partners to extend their reach. Clients range from public health authorities, non-profit entities to clinical and referece laboratories.

Established in 1992, Trinity Biotech continues to operate from its headquarters stationed in Bray, Ireland.

Sector:
Country:Ireland
Industry:
Address:IDA Business Park Southern Cross Road, Bray, DUBLIN
Employees:401
Website:trinitybiotech.com

Pros

Recurring revenue from diagnostic reagents and consumables

High regulatory barriers to entry in medical diagnostics

Established global distribution network for diagnostic products

Increasing prevalence of chronic diseases driving demand

Specialized focus in niche diagnostic testing segments

Cons

Intense competition from larger diagnostic companies

Pros

Cons

Company

AI Score

Compare

BLLNBillionToOne Inc

BMRABiomerica Inc

INBSIntelligent Bio Solutions Inc

HCTIHealthcare Triangle Inc

QDELQuidelOrtho Corp

Company

AI Score

Compare

TRIB Top 10 Industry Stocks

Health Care Equipment & Supplies

	Company	AI Score	Compare
1	UTMDUtah Medical Products Inc
2	CVRXCVRx Inc
3	PODDInsulet Corp
4	ADGMAdagio Medical Holdings Inc
5	XTNTXtant Medical Holdings Inc
6	TMDXTransmedics Group Inc
7	GUTSFractyl Health Inc
8	PDEXPro-Dex Inc
9	PHGKoninklijke Philips NV
10	ALCAlcon AG

	Company	AI Score	Compare

	Company	AI Score	Compare
1	COGTCogent Biosciences Inc

Company

AI Score

Compare

COGTCogent Biosciences Inc

Company

AI Score

Compare

TRIB Stock AI Analysis